(Q44118279)

30 November 2017

Treatment of relapsed or refractory adult acute lymphocytic leukemia (English)

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

author name string

M. Freund

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

H. Diedrich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

A. Ganser

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

M. Gramatzki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

G. Heil

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

A. Heyll

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

M. Henke

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

W. Hiddemann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

R. Haas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

R. Kuse

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1730121

10 November 2022

language of work or name

English

0 references

publication date

1 February 1992

1 reference

full work available at URL

30 November 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

1 reference

30 November 2017

69

1 reference

30 November 2017

709-716

1 reference

30 November 2017

3

1 reference

Reporting results of cancer treatment

30 November 2017

5

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Cancer chemotherapy reports

10 November 2022

6

55

269

Ohnuma

1971

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Nonparametric Estimation from Incomplete Observations

10 November 2022

7

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Combination chemotherapy for haematological relapse in adult acute lymphoblastic leukaemia (ALL)

10 November 2022

9

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

Cancer Treatment Reports

11

63

1413

Elias

1979

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia

10 November 2022

12

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation

10 November 2022

13

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

10 November 2022

15

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

10 November 2022

16

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

10 November 2022

17

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Scandinavian journal of haematology. Supplementum

10 November 2022

21

44

7

Peters

1986

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

Cancer Treatment Reports

23

69

1447

Zittoun

1985

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin.

10 November 2022

25

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

10 November 2022

27

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma

10 November 2022

30

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia

10 November 2022

31

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

10 November 2022

32

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia

10 November 2022

33

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

High-dose ara-C and etoposide in refractory or relapsing acute leukemia

10 November 2022

35

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse

10 November 2022

36

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

Cancer Treatment Reports

37

65

83

Yap

1981

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Results of a Cancer and Leukemia Group B Study

10 November 2022

38

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate

10 November 2022

39

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia

10 November 2022

40

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor

10 November 2022

41

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

Hamatologie und Bluttransfusion

10 November 2022

43

33

619

Henze

1990

1 reference

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19920201)69:3%3C709::AID-CNCR2820690318%3E3.0.CO;2-G

10 November 2022

Identifiers

10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G

1 reference

30 November 2017

1 reference